Peptides as targets for antihypertensive drug development

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Drug Discovery

Background:

• The renin-angiotensin system has been a key target for hypertension treatment, with ACE inhibitors and Ang II receptor antagonists showing success.
• Pharmacological modulation of vasoactive peptides, including atrial natriuretic peptide (ANP) and neuropeptides, offers new avenues for blood pressure control.
• Inhibiting renin activity presents challenges due to compensatory increases in active renin, while ANP enhancement and blockade of vasopressor peptides are promising.

Purpose of the Study:

• To explore the potential for developing novel pharmacological drug classes for hypertension and cardiovascular disease treatment.
• To review current and future targets for antihypertensive drug development based on vasoactive peptide interactions.

Main Methods:

• Review of established and emerging pharmacological targets in hypertension management.
• Analysis of the role of vasoactive peptides and their modulation in cardiovascular function.
• Evaluation of drug classes such as ACE inhibitors, Ang II receptor antagonists, renin inhibitors, and peptide-modulating agents.

Main Results:

• Blockade of the renin-angiotensin system, particularly via Ang II type 1 receptor antagonists, is an established therapeutic strategy.
• Pharmacologically increasing atrial natriuretic peptide (ANP) availability through NEP-24.11 inhibition shows potential for hypertension and heart failure.
• Neuropeptide Y1 receptor antagonists and endothelin antagonists represent promising targets for novel antihypertensive agents.

Conclusions:

• Future drug development will likely focus on interactions with vasoactive peptides.
• These novel agents hold the potential to significantly improve the management of specific cardiovascular diseases.
• Continued research into peptide-based therapies is crucial for advancing cardiovascular medicine.